Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 7/20 | 0.47 |
| ▸ | F2 | P00734 | 5/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297341 | 0.86 | NPC1 (0.55) | MEN1KMT2ACCR5SIGMAR1KCNH2 | |
| SCHEMBL4283829 | 0.84 | CCR5 (0.62) | KMT2ACCR5SIGMAR1KCNH2 | |
| SCHEMBL11394433 | 0.82 | SIGMAR1 (0.64) | MEN1KMT2ACCR5SIGMAR1 | |
| SCHEMBL7040051 | 0.82 | ALDH1A1 (0.54) | MEN1KMT2AF2 | |
| SCHEMBL11626650 | 0.80 | MAP4K4 (0.57) | MEN1KMT2AMAP4K4CCR5PABPC1 | |
| SCHEMBL13956186 | 0.79 | MEN1 (0.49) | MEN1KMT2AMAP4K4CCR5SIGMAR1 | |
| SCHEMBL2405156 | 0.78 | CCR5 (0.60) | CCR5SIGMAR1KCNH2 | |
| SCHEMBL2407533 | 0.78 | KCNH2 (0.49) | MEN1KMT2ACCR5SIGMAR1KCNH2 | |
| SCHEMBL19444606 | 0.77 | CCR5 (0.64) | MEN1KMT2AMAP4K4CCR5 | |
| SCHEMBL17896798 | 0.77 | NPC1 (0.56) | MEN1KMT2AMAP4K4CCR5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1924561-B1 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR1A, HTR2A | MEN1 4387/4885KMT2A 1221/4885MAP4K4 3573/4885 |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR1A, HTR2A | MEN1 4387/4885KMT2A 1221/4885MAP4K4 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.